“FDA CREATES AN UNAUTHORIZED “POCKET BAN” AUTHORITY ON KRATOM BY ABUSING ITS IMPORT ALERT AUTHORITY!
Recent Action Puts Millions of Americans at Risk of Immediate Public Health Consequences!
WASHINGTON, DC (May 2023) — Recent action by the U.S. Food and Drug Administration (“FDA”) to initiate a seizure action on kratom products manufactured and marketed by Botanic Tonics based on “serious safety concerns” by the FDA is directly contradicted by a substantial body of current evidence and data on the safety and addiction profile of kratom.
This FDA action is targeted at a kratom community of 15 million Americans who safely and responsibly use kratom to deny consumer access to kratom products as a “pocket ban” on all kratom products in the United States because FDA has failed to justify a recommendation to classify kratom as a Schedule I substance under the federal Controlled Substances Act (“CSA”).“
